Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A.
Abdelmagid MG, et al. Among authors: gangat n.
Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x.
Blood Cancer J. 2023.
PMID: 37567878
Free PMC article.